Drug intelligence / Profile preview

veratrine

Development stage
Discontinued
Lead developer
MGK
Modality
Small Molecules
Administration
Topical, External, Oral (discouraged And Not Recommended Due To Toxicity)
01

Overview

Veratrine is a **mixture of alkaloids** obtained primarily from the seeds of *Schoenocaulon officinale* (sabadilla), and historically sometimes from other plants in the Veratrum genus. This mixture contains mostly **cevadine** and **veratridine**, along with other minor alkaloids. It appears as a white or greyish-white powder, very slightly soluble in water but more soluble in solvents like alcohol, ether, and chloroform[1][5]. Veratrine is **not a single, well-defined compound**, but rather an amorphous, variable mixture[1]. Its pharmacological actions are primarily due to **interaction with voltage-gated sodium channels**, leading to increased nerve and muscle excitability, tingling, and numbness when applied topically, and potentially causing severe toxic effects with systemic exposure[1][2][4]. Veratrine has been used **externally for neuralgia** as an analgesic and counterirritant, and as a **parasiticide** (notably for lice), but is largely obsolete in medical use due to its **toxicity**[1][2][4]. It continues to find use as a **botanical insecticide** due to its neurotoxic actions on pests[4]. Internally, its use is considered unsafe because of severe irritant and toxicological effects.

Other names
veratrinaveratrinum
02

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)SCN9A (Sodium channel protein type 9 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)

Beyond the preview

Go deeper on veratrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on veratrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call